Search results for: NICE
Filter search results
OHE Seminar Launches ‘An EQ-5D-5L Value Set for England’
13 November 2014
…for England’. The seminar was well attended, with participants from the Department of Health, NICE, NHS England, the EuroQol Group, academia and pharmaceutical industry. The EQ-5D is widely used to…
New Business Models for Antibiotics. What Can We Learn from Other Industries?
7 April 2015
…at the different types of incentives that might increase returns to antibiotics’ R&D. Access this work here. This work also feeds nicely in to further ongoing initiatives being driven by IMI…
Patient-reported outcomes measures (PROMs) in Health Economics – an Overview and Key Developments in the Field
30 June 2015
…Excellence (NICE). Since 2009, PROMs data, including the EQ-5D, have been routinely collected across English NHS providers of four key elective interventions. In her presentation, Nancy introduced the use of…
Guest post: The Economics of Elevated Hospital Mortality at Weekends
14 July 2015
…Using the NICE £20,000 per QALY threshold, the NHS should spend no more than £595m – £731m to achieve a health gain of this size. Whilst the potential benefits…
OHE at ISPOR Europe: Milan 2015
1 December 2015
…and advising; academic institutions; and public policy making. This included comments on: his role in reorganising NHS R&D, and in setting up NICE; his theoretical contribution to extra-welfarism, and to…
New publication: Using Patient Reported Outcomes to Improve Health Care
21 December 2015
…the book, Professor Kalipso Chalkidou (NICE international) stresses the importance and relevance of PROs: “They [PROs] can empower patients in making choices about their treatment…They can boost policy makers’ efforts…
New Publication: Headroom Approach to Device Development
23 February 2016
…C., & Girling, A., 2014. Are the UK systems of innovation and evaluation of medical devices compatible? The role of NICE’s medical technologies evaluation programme (MTEP). Applied Health Economics and…
Spotlight on OHE: Beyond QALYs, Managed Entry Agreements, Business Models for Antibiotics, and the UK Market for Medicines.
12 April 2016
…the lowest in developed countries. The second half of the lecture looked at NICE and the ‘hurdle’ of demonstrating cost-effectiveness, as well as an overview of pricing regulation, and specific…
OHE Presentations at HTAi: Tokyo 2016
24 May 2016
…the evidence in the UK on the opportunity cost of NICE decisions, looking at the Claxton et al. work, the Barnsley et al critique, and work by Karlsberg Schaffer et…